P783 Long-term colectomy rate in acute severe ulcerative colitis. An observational multi-centre study on behalf of IG-IBD (Italian group for the study of inflammatory bowel disease)

Abstract First detected in Wuhan, China, the novel 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA beta-coronavirus responsible for an unprecedented, worldwide pandemic caused by COVID-19. Optimal management of immunosuppression in inflammatory bowel disease (IBD) patients with COVID-19 infection currently is based on expert opinion, given the novelty of the infection and the corresponding lack of high-level evidence in patients with immune-mediated conditions. There are limited data regarding IBD patients with COVID-19 and no data regarding early pregnancy in the era of COVID-19. This article describes a patient with acute severe ulcerative colitis (UC) during her first trimester of pregnancy who also has COVID-19. The case presentation is followed by a review of the literature to date on COVID-19 in regard to inflammatory bowel disease and pregnancy, respectively.

Download Full-text

OC.02.3 A REAL LIFE COMPARISON OF THE EFFECTIVENESS OF ADALIMUMAB VERSUS GOLIMUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS. A MULTICENTRE EXPERIENCE FROM A REGIONAL NETWORK FOR INFLAMMATORY BOWEL DISEASE

Digestive and Liver Disease ◽

10.1016/s1590-8658(18)30275-5 ◽

2018 ◽

Vol 50 (2) ◽

pp. e72

Author(s):

S. Renna ◽

F. Mocciaro ◽

M. Ventimiglia ◽

R. Orlando ◽

F.S. Macaluso ◽

...

Keyword(s):

Ulcerative Colitis ◽

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Real Life ◽

Regional Network ◽

Severe Ulcerative Colitis ◽

Inflammatory Bowel

Download Full-text

Cytomegalovirus Infection in Pediatric Severe Ulcerative Colitis—A Multicenter Study from the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition

The Pediatric Infectious Disease Journal ◽

10.1097/inf.0000000000001724 ◽

2018 ◽

Vol 37 (3) ◽

pp. 197-201 ◽

Cited By ~ 5

Author(s):

Shlomi Cohen ◽

Christine Martinez-Vinson ◽

Marina Aloi ◽

Dan Turner ◽

Amit Assa ◽

...

Keyword(s):

Ulcerative Colitis ◽

Inflammatory Bowel Disease ◽

Multicenter Study ◽

European Society ◽

Bowel Disease ◽

Cytomegalovirus Infection ◽

Pediatric Gastroenterology ◽

Severe Ulcerative Colitis ◽

Pediatric Inflammatory Bowel Disease ◽

Inflammatory Bowel

Download Full-text

Sa1888 – Ustekinumab Therapy Induced Clinically Meaningful Improvement and Remission As Measured by the Inflammatory Bowel Disease Questionnaire in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 Unifi Induction and Maintenance Studies

Gastroenterology ◽

10.1016/s0016-5085(19)37954-5 ◽

2019 ◽

Vol 156 (6) ◽

pp. S-442-S-443

Author(s):

Bruce E. Sands ◽

Chenglong Han ◽

Hongyan Zhang ◽

Jewel Johanns ◽

Philippe Szapary ◽

...

Keyword(s):

Ulcerative Colitis ◽

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Phase 3 ◽

Meaningful Improvement ◽

Inflammatory Bowel Disease Questionnaire ◽

Severe Ulcerative Colitis ◽

Inflammatory Bowel ◽

Disease Questionnaire

Download Full-text

Botanical Drugs as an Emerging Strategy in Inflammatory Bowel Disease: A Review

Mediators of Inflammation ◽

10.1155/2015/179616 ◽

2015 ◽

Vol 2015 ◽

pp. 1-14 ◽

Cited By ~ 21

Author(s):

Francesca Algieri ◽

Alba Rodriguez-Nogales ◽

M. Elena Rodriguez-Cabezas ◽

Severiano Risco ◽

M. Angeles Ocete ◽

...

Keyword(s):

Ulcerative Colitis ◽

Inflammatory Bowel Disease ◽

Clinical Trials ◽

Bowel Disease ◽

Life Quality ◽

Beneficial Effects ◽

New Strategy ◽

Inflammatory Bowel ◽

Surgical Treatments

Crohn’s disease and ulcerative colitis are the two most common categories of inflammatory bowel disease (IBD), which are characterized by chronic inflammation of the intestine that comprises the patients’ life quality and requires sustained pharmacological and surgical treatments. Since their aetiology is not completely understood, nonfully efficient drugs have been developed and those that show effectiveness are not devoid of quite important adverse effects that impair their long-term use. Therefore, many patients try with some botanical drugs, which are safe and efficient after many years of use. However, it is necessary to properly evaluate these therapies to consider a new strategy for human IBD. In this report we have reviewed the main botanical drugs that have been assessed in clinical trials in human IBD and the mechanisms and the active compounds proposed for their beneficial effects.

Download Full-text